To identify metabolic vulnerabilities in CML LSCs, we compared the steady-state levels of 70 key metabolites of fatty acid, amino acid, glucose and energy metabolism from CML patients-derived
CD34
+ cells with their normal counterparts. We found higher levels of carnitine and acylcarnitine derivatives and lower levels of free fatty acids in CML CD34 + cells, suggesting a potential upregulation of lipolysis and fatty acid oxidation (FAO; Figure 1 ). Furthermore, both stable isotopeassisted metabolomic analysis, using uniformly 13 C 16 -labelled palmitate or 13 C 16 -labelled glucose, and functional assays measuring the oxygen consumption rate revealed a clear upregulation of the overall oxidative metabolism in CML CD34 + cells compared to their normal counterparts [5] .
Interestingly, CML CD34 + cells also showed lower lactate levels and increased oxidative and anaplerotic activity compared to the more differentiated CD34 -fraction, suggesting that primitive CML cells rely preferentially on oxidative metabolism rather than glycolysis [5] . Similar 13 C isotopic enrichment experiments revealed that treatment with tigecycline reduced the amount of labelled carbons in tricarboxylic acid (TCA) cycle intermediates, proving that tigecycline can effectively inhibit the oxidative metabolism of LSCs. Our data also shows that treating CML cells with a combination of tigecycline and imatinib almost fully inhibits the colony formation capacity of CML progenitors and long-term stem cells [5] . Interestingly, the drug combination did not elicit the same effect in normal haematopoietic CD34 + cells, ruling out the potential for broad cytotoxicity.
Importantly, as mitochondria constitute the main source of reactive oxygen species (ROS) in cells, our results may explain previous studies showing that LSCs present higher levels of ROS and DNA damage than normal HSCs [7] . Our findings indeed support the in vivo experiments results obtained by Bolton-Gillespie et al., which report higher levels of ROS in primitive cells compared to the more differentiated compartment within the bone marrow of leukaemic mice. Other studies on cancer stem cells, including in AML, have shown that these primitive cells rely more heavily on oxidative phosphorylation (OXPHOS) to supply their energetic demands compared to bulk tumour cells and normal stem cells, regardless of the low-ROS levels found in the more quiescent AML stem cells [8] .
Therefore, elucidating the link between mitochondria, ROS generation and stemness in CML LSCs represent an attractive topic for future investigation. Lastly, using single-cell RNA sequencing coupled with a highly sensitive BCR-ABL detection method, Giustacchini et al. elegantly showed in a recent study that primitive BCR-ABL + cells from CML patients presented an overexpression of OXPHOS and FAO-related genes when compared to their bystander BCR-ABL -counterparts [9] . This further suggests that the oxidative phenotype we characterised is specific to LSCs in patients, further
highlighting the clinical relevance of our findings.
Using a well-established xenotransplant model of human CML, we also tested the effect of tigecycline treatment alone or in combination with imatinib in vivo. The combination treatment drastically reduced the number of the most primitive long-term engrafting cells. In order to investigate whether this combination was also effective in preventing relapse, we treated xenografted CML cells with tigecycline alone or in combination for a period of four weeks, then discontinued the treatment for two or three weeks. Strikingly, mice treated with the drug combination maintained a low number of LSCs after treatment discontinuation, whereas similar levels of LSCs were found in imatinib treated mice and untreated mice. These results reveal that combining tigecycline with imatinib might prevent disease relapse in CML patients with minimal residual disease. 
